Seeking Alpha

Shares of BioLineRX (BLRX) soar 31.1% in premarket trading after the firm announces that it...

Shares of BioLineRX (BLRX) soar 31.1% in premarket trading after the firm announces that it signed an exclusive agreement with French-based Genoscience to develop and commercialize its Hepatitis C treatment.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|